Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenous administration) and SPL028 (intravenous and intramuscular administration) in healthy volunteers.
Both compounds are novel deuterated DMT molecules within the company’s next-gen psychedelics program targeting Generalized Anxiety Disorder (GAD.) DMT is a hallucinogenic tryptamine drug that naturally occurs in several plant species and animals, including humans.
See Also: Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
Results showed:
CYB004 produced “robust” psychedelic effects. Although the general rule of the stronger the dose, the more intense the experience, Cybin’s deuterated DMT reportedly provided a stronger experience even ...